1. Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. Feigin ME, Akshinthala SD, Araki K, Rosenberg AZ, Muthuswamy LB, Martin B, Lehmann BD, Berman HK, Pietenpol JA, Cardiff RD, Muthuswamy SK (2014) Cancer Res 74(11): 3180-94
    › Primary publication · 24662921 (PubMed) · PMC4096808 (PubMed Central)
  2. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. Lehmann BD, Pietenpol JA (2014) J Pathol 232(2): 142-50
    › Primary publication · 24114677 (PubMed) · PMC4090031 (PubMed Central)
  3. Detection of internal exon deletion with exon Del. Guo Y, Zhao S, Lehmann BD, Sheng Q, Shaver TM, Stricker TP, Pietenpol JA, Shyr Y (2014) BMC Bioinformatics : 332
    › Primary publication · 25322818 (PubMed) · PMC4288651 (PubMed Central)
  4. Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Landis MD, Lehmann BD, Pietenpol JA, Chang JC (2013) Breast Cancer Res 15(1): 201
    › Primary publication · 23339383 (PubMed) · PMC3672825 (PubMed Central)
  5. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, Pietenpol JA, Shao ZM, Symmans WF, Chang JC (2013) Clin Cancer Res 19(10): 2723-33
    › Primary publication · 23549873 (PubMed) · PMC3655097 (PubMed Central)
  6. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT (2013) Clin Cancer Res 19(19): 5533-40
    › Primary publication · 23948975 (PubMed) · PMC3813597 (PubMed Central)
  7. Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control. Guo Y, Sheng Q, Samuels DC, Lehmann B, Bauer JA, Pietenpol J, Shyr Y (2013) Biomed Res Int : 915636
    › Primary publication · 24303503 (PubMed) · PMC3835197 (PubMed Central)
  8. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W (2013) Clin Cancer Res 19(24): 6696-702
    › Primary publication · 24345920 (PubMed) · PMC3880773 (PubMed Central)
  9. TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, Pietenpol JA (2012) Cancer Inform : 147-56
    › Primary publication · 22872785 (PubMed) · PMC3412597 (PubMed Central)
  10. Targeting mutant p53 in human tumors. Lehmann BD, Pietenpol JA (2012) J Clin Oncol 30(29): 3648-50
    › Primary publication · 22965952 (PubMed)